GLAXOSMITHKLINE'S pharmaceuticals and vaccines business in Australia recorded almost $1 billion in revenue last year, with a pre-tax profit of $47m.
According to data provided to the Australian Securities and Investments Commission by the company, GSK Consumer Healthcare Australia also recorded revenue of $411 million and profit before tax of $33 million with key brands including Panadol, Voltaren, Sensodyne and Polident.
The HIV-focused ViiV Healthcare joint venture with Pfizer reported sales of $78 million, up 35% and a pre-tax profit of $2.7 million.
See au.gsk.com for more detail.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 May 17